Multiple Sclerosis

John Corboy, MD, professor of neurology at the University of Colorado, discussed recent findings focused on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis.

Actress Jamie Lynn Sigler discussed how patient education, treatment adherence, and self-advocacy have shaped her approach to living with multiple sclerosis at the 2026 CMSC Annual Meeting.

Carrie Hersh, DO, MSc, FAAN, president of the Consortium of Multiple Sclerosis Centers, discussed key sessions presented on disability progression, emerging biomarkers, and the shift toward comprehensive, patient-centered MS care.

Ahmed Obeidat, MD, PhD, associate professor of neurology at the Medical College of Wisconsin, talked about the need to rethink multiple sclerosis clinical trial design by recognizing immune cells’ potential neuroprotective roles.

Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, director of the multiple sclerosis research unit at Ottawa Hospital, outlined how research-integrated multiple sclerosis care can refine treatment strategies in clinical practice.

A cross-sectional survey of 4181 NARCOMS Registry participants found that only 7.4% had ever used semaglutide or tirzepatide, despite 40% meeting FDA-approved indications for the drugs.

The first randomized, double-blind trial directly comparing the 2 anti-CD20 agents showed rituximab met the prespecified noninferiority criterion on MRI suppression, with a similar serious adverse event profile and a substantially lower cost.

TG Therapeutics has indicated it plans to submit a supplemental BLA to the FDA in the second half of 2026, seeking approval for the consolidated initiation regimen of ublituximab-xiiy.

The 510(k) clearance was supported by a 3-study, 159-patient registrational program showing a 45.5% increase in response rate vs physical therapy alone, and includes Medicare coverage at launch.

Tom Fuchs, MD, PhD, postdoctoral researcher at the MS Center at Amsterdam University Medical Center, shared his reaction to the European Commission's approval of tolebrutinib for nonrelapsing secondary progressive MS.

Jens Kuhle, MD, PhD, head of the Multiple Sclerosis Centre at University Hospital Basel, discusses the EU approval of tolebrutinib for nonrelapsing SPMS and its implications for treating disability progression.

The European Commission has approved Cenrifki (tolebrutinib) for nrSPMS without relapses in the last two years, a milestone that arrives despite the drug's failed US submission and a regulatory pathway that has been anything but linear.

FDA’s clearance for PTD802, a first-in-class GPR17 antagonist designed to promote remyelination, enables initiation of a first-in-human phase 1 study in healthy volunteers and advances a novel regenerative approach for multiple sclerosis.

Neurologists Sarah Simmons, MD, PhD, and Fatma Inanici, MD, PhD, discuss how the combination of noninvasive cervical spinal cord stimulation with exercise therapy can improve upper extremity function in people with MS.

Daniel Vitt, PhD, chief executive officer of Immunic, discussed the dual mechanism of vidofludimus calcium, ongoing phase 3 ENSURE trials in relapsing MS, and phase 2 CALLIPER findings suggesting potential neuroprotective effects in progressive MS.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 5, 2026.

As the MS community reflects on World MS Day, Alla Wilson, a clinical ambulatory pharmacist at Shields Health Solutions, discusses how integrated specialty pharmacy models can improve treatment access, adherence, and patient-reported outcomes for multiple sclerosis.

The assistant professor of neurology at NYU Grossman School of Medicine discussed how optical coherence tomography can support the 2024 McDonald Criteria for multiple sclerosis at CMSC 2026.

A clinical research coordinator at SunnyBrook Health Sciences Centre, explained key factors of the computerized cognitive training program that contributed to cognitive improvement. [WATCH TIME: 3 minutes]

The neurologist at St. Michael's Hospital shared findings presented at CMSC 2026 from a large dataset on preconception ocrelizumab exposure among women with multiple sclerosis. [WATCH TIME: 5 minutes]

At CMSC 2026, Jamie Lynn Sigler, an actress and patient advocate, shared her perspective on living with multiple sclerosis, emphasizing informed decision-making and treatment consistency. [WATCH TIME: 7 minutes]

The director of the Stony Broke MS Comprehensive Care Center reviewed late-breaking subgroup data evaluating high-efficacy therapy in patients with highly active relapsing multiple sclerosis and discussed the evolving role of early intervention. [WATCH TIME: 5 minutes]

New data presented at CMSC 2026 suggest ocrelizumab provides comparable relapse and MRI control in pediatric- and young-adult–onset multiple sclerosis, with greater disability improvement observed in pediatric patients.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed important behind the scenes work nurses carry out in neurology care.

German 3-year real-world data shows ozanimod keeps RRMS relapses low, disability stable, and safety consistent in routine care.